Taiho and Cullinan halt their first-line EGFR exon 20 lung cancer trial early with zipalertinib — the data was too good to stay blinded — raising the bar for J&J's Rybrevant, AstraZeneca and Dizal's Zegfrovy, and ArriVent's firmonertinib. Also: Definium's DT120 separates from placebo by 5.4 points in Phase 3 generalized anxiety from a single dose of pharmaceutical-grade LSD — and the stock gives back a third of its pop. Plus Karyopharm faces default on a September loan payment as it files Xpovio in myelofibrosis, and Eli Lilly escalates its fight against the retatrutide black market. Visit us at thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →